Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study

This 56-week phase 3, open-label, treat-to-target study, involving 2 consecutive, non-randomized cohorts, evaluated the safety and tolerability of azilsartan medoxomil (AZL-M) in essential hypertension (mean baseline blood pressure [BP] 152/100 mmHg). All subjects (n = 669) initiated AZL-M 40 mg QD,...

Descripción completa

Detalles Bibliográficos
Autores principales: Handley, Alison, Lloyd, Eric, Roberts, Andrew, Barger, Bruce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819839/
https://www.ncbi.nlm.nih.gov/pubmed/26817604
http://dx.doi.org/10.3109/10641963.2015.1081213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819839/
https://www.ncbi.nlm.nih.gov/pubmed/26817604
http://dx.doi.org/10.3109/10641963.2015.1081213

Ejemplares similares